Financial derivatives exchange CME Group (NASDAQ:CME) met Wall Streets revenue expectations in Q4 CY2025, with sales up 8.1% year on year to $1.65 billion. Its non-GAAP profit of $2.77 per share was 1% above analysts’ consensus estimates.

Is now the time to buy CME Group? Find out in our full research report.

Revenue: $1.65 billion vs analyst estimates of $1.64 billion (8.1% year-on-year growth, in line)

Pre-tax Profit: $1.58 billion (95.7% margin)

Adjusted EPS: $2.77 vs analyst estimates of $2.74 (1% beat)

Market Capitalization: $105.7 billion

"Last year, CME Group delivered the best year in our history and our fourth consecutive year of record revenue, adjusted operating income, adjusted net income and adjusted earnings per share," said Terry Duffy, CME Group Chairman and Chief Executive Officer.

Born from the Chicago Mercantile Exchange founded in 1898 as a butter and egg trading venue, CME Group (NASDAQ:CME) operates the world's largest derivatives marketplace where traders can buy and sell futures and options contracts across interest rates, equities, currencies, commodities, and more.

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, CME Group grew its revenue at a tepid 6% compounded annual growth rate. This was below our standard for the financials sector and is a tough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within financials, a half-decade historical view may miss recent interest rate changes, market returns, and industry trends. CME Group’s annualized revenue growth of 8.1% over the last two years is above its five-year trend, suggesting some bright spots.

Note: Quarters not shown were determined to be outliers, impacted by outsized investment gains/losses that are not indicative of the recurring fundamentals of the business.

This quarter, CME Group grew its revenue by 8.1% year on year, and its $1.65 billion of revenue was in line with Wall Street’s estimates.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our free report one of our favorites growth stories.

This was a quarter without many surprises, good or bad. Revenue was in line and EPS beat by 1%. The stock remained flat at $293.04 immediately following the results.

So should you invest in CME Group right now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it’s free.